Novonesis (Novozymes) B (FRA:NZM) FFO


FRA:NZM Novonesis (Novozymes) B FRA:NZM
88 GF Score
Price €53.00
GF Value €55.23
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B FFO?

FFO (Funds from operations) only applies to REITs.

FRA:NZM
88GF Score
Novonesis (Novozymes) B FRA:NZM
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novonesis (Novozymes) B (FRA:NZM) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be undervalued. The current stock price of €53.00 is trading 4% below its estimated GF Value™ of €55.23. GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.

Key valuation signals for FRA:NZM:

  • FFO:
  • GF Value™: €55.23 vs. price of €53.00 (4% below fair value)
  • GF Score™: 88/100 with 3 warning signs

No single metric tells the full story. See the FRA:NZM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
88GF Score

Get the complete analysis for FRA:NZM

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€53.00
Price
€55.23
GF Value